Increasing tobacco taxes: A cheap tool to increase public health

Health Policy

Volumn 82, Issue 2, 2007, Pages 142-152

  van Baal, Pieter H M ^a   Brouwer, Werner B F ^b   Hoogenveen, Rudolf T ^a   Feenstra, Talitha L ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness analyses; Dynamic modelling; Medical costs in life years gained; Tobacco taxes

Indexed keywords

ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; POPULATION MODEL; PREVALENCE; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; SMOKING CESSATION; TAX; TOBACCO;

COST-BENEFIT ANALYSIS; HUMANS; NETHERLANDS; PUBLIC HEALTH; SMOKING; TAXES;

EID: 34249080890     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.09.004     Document Type: Article

References (58)

1. US Department of Health and Human Services. Reducing tobacco use: a report of the surgeon general. 2000.
2. STIVORO. Roken, de harde feiten: Volwassenen 2003. Den Haag: STIVORO.
3. STIVORO. Roken, de harde feiten: Volwassenen 2004. Den Haag: STIVORO.
4. STIVORO. Roken, de harde feiten: Volwassenen 2005. Den Haag: STIVORO.
5. STIVORO. Roken, de harde feiten: Volwassenen 2002. Den Haag: STIVORO.
6. de Hollander AEM, Hoeymans N, Melse J, van Oers J, Polder JJ. Zorg voor gezondheid-Volksgezondheid Toekomst Verkenning 2006. 2006; RIVM Report 270061003.
7. Ezzati M., Hoorn S.V., Rodgers A., Lopez A.D., Mathers C.D., and Murray C.J. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 362 9380 (2003) 271-280
8. Feenstra T.L., Hamberg-van Reenen H.H., Hoogenveen R.T., and Rutten-van Molken M.P. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value in Health 8 3 (2005) 178-190
9. Ronckers E.T., Groot W., and Ament A.J. Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness. Medical Decision Making 25 4 (2005) 437-448
10. Parrott S., Godfrey C., Raw M., West R., and McNeill A. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health educational authority. Thorax 53 Suppl. 5, Pt. 2 (1998) S1-S38
11. Drummond M.F., O'Brien B., Stoddart G.L., and Torrance G.W. Methods for the economic evaluation of health care programmes. 2nd ed. (1997), Oxford University Press, Oxford
12. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
13. Statistics Netherlands. Statline [online database] [Web Page] (accessed October 2005).
14. Murray C.J., Lopez A.D., and Wibulpolprasert S. Monitoring global health: time for new solutions. BMJ 329 7474 (2004) 1096-1100
15. Keeler T.E., Hu T.W., Barnett P.G., Manning W.G., and Sung H.Y. Do cigarette producers price-discriminate by state? An empirical analysis of local cigarette pricing and taxation. Journal of Health Economics 15 4 (1996) 499-512
16. Gallet C.A., and List J.A. Cigarette demand: a meta-analysis of elasticities. Health Economics 12 10 (2003) 821-835
17. Jha P., and Chaloupka F.J. Curbing the epidemic: governments and the economics of tobacco control (1999), The World Bank, Washington, DC [development in practice]
18. Emery S., Ake C.F., Navarro A.M., and Kaplan R.M. Simulated effect of tobacco tax variation on Latino health in California. American Journal of Preventive Medicine 21 4 (2001) 278-283
19. Ahmad S. Increasing excise taxes on cigarettes in California: a dynamic simulation of health and economic impacts. Preventive Medicine 41 1 (2005) 276-283
20. Levy D.T., Cummings K.M., and Hyland A. Increasing taxes as a strategy to reduce cigarette use and deaths: results of a simulation model. Preventive Medicine 31 3 (2000) 279-286
21. Ranson M.K., Jha P., Chaloupka F.J., and Nguyen S.N. Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies. Nicotine and Tobacco Research 4 3 (2002) 311-319
22. Barendregt J.J., Bonneux L., and van der Maas P.J. The health care costs of smoking. The New England Journal of Medicine 337 15 (1997) 1052-1057
23. Hoogenveen RT, de Hollander AEM, van Genugten MLL. The chronic disease modelling approach. 1998; RIVM Report 266750001.
24. van Genugten M.L., Hoogenveen R.T., Mulder I., Smit H.A., Jansen J., and de Hollander A.E. Future burden and costs of smoking-related disease in The Netherlands: a dynamic modeling approach. Value in Health 6 4 (2003) 494-499
25. Mulder I., Genugten MLLv, Hoogenveen R.T., Hollander AEMd, and Bueno-de-Mesquita H.B. The impact of smoking on future pancreatic cancer: a computer simulation. Annals of Oncology 10 Suppl. 4 (1999) 74-78
26. Struijs J.N., van Genugten M.L., Evers S.M., Ament A.J., Baan C.A., and van den Bos G.A. Modeling the future burden of stroke in The Netherlands: impact of aging, smoking, and hypertension. Stroke 36 8 (2005) 1648-1655
27. Feenstra T.L., van Genugten M.L., Hoogenveen R.T., Wouters E.F., and Rutten-van Molken M.P. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in The Netherlands. American Journal of Respiratory and Critical Care Medicine 164 4 (2001) 590-596
28. Chaloupka F.J., and Warner K.E. The economics of smoking. Handbook of health economics (2000), Elsevier, Amsterdam
29. Douglas S. The duration of the smoking habit. Economic Inquiry 36 1 (1998) 49-64
30. Forster M., and Jones A.M. The role of tobacco taxes in starting and quitting smoking: duration analysis of British data. Journal of the Royal Statistical Society: Series A 164 3 (2001) 517-547
31. Lopez Nicolas A. How important are tobacco prices in the propensity to start and quit smoking? An analysis of smoking histories from the Spanish National Health Survey. Health Economics 11 6 (2002) 521-535
32. Evans W.N., and Farrelly M.C. The compensating behavior of smokers: taxes, tar, and nicotine. Rand Journal of Economics 29 3 (1998) 578-595
33. Riteco J.A., de Heij L.J.M., Luijn J.C.F., and Wolff I.R. Richtlijnen voor farmaco-economisch onderzoek [guidelines for pharmacoeconomic research] (1999), College Voor Zorgverzekeringen, Amstelveen
34. Polder JJ, Takken J, Meerding WJ, Kommer GJ, Stokx LJ. Cost of Illness in The Netherlands [Internet]. Available from: http://www.rivm.nl/kostenvanziekten. Bilthoven: National Institute of Public Health and the Environment (RIVM) 2002.
35. Bonneux L., Barendregt J.J., Nusselder W.J., and der Maas P.J. Preventing fatal diseases increases healthcare costs: cause elimination life table approach. BMJ 316 7124 (1998) 26-29
36. Rasmussen S.R., Prescott E., Sorensen T.I., and Sogaard J. The total lifetime health cost savings of smoking cessation to society. European Journal of Public Health 15 6 (2005) 601-606
37. Rasmussen S.R., Prescott E., Sorensen T.I., and Sogaard J. The total lifetime costs of smoking. European Journal of Public Health 14 1 (2004) 95-100
38. Joossens L., and Raw M. Cigarette smuggling in Europe: who really benefits?. Tobacco Control 7 1 (1998) 66-71
39. Brouwer W.B., van Exel N.J., Baltussen R.M., and Rutten F.F. A dollar is a dollar is a dollar-or is it?. Value Health 9 (2006) 341-347
40. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. Journal of Health Economics 16 1 (1997) 33-64
41. Nyman J.A. Should the consumption of survivors be included as a cost in cost-utility analysis?. Health Economics 13 5 (2004) 417-427
42. Brouwer W.B., and Koopmanschap M.A. On the economic foundations of CEA. Ladies and gentlemen, take your positions!. Journal of Health Economics 19 4 (2000) 439-459
43. Hoogenveen RT, Gijsen R. Dutch DisMod for several types of cancer. 2000; RIVM Report 260751004.
44. Hoogenveen RT, Gijsen R., van Genugten MLL, Kommer GJ, Schouten JSAG, de Hollander AEM. Dutch DisMod. Constructing a set of consistent data for chronic disease modelling. 2000; RIVM Report 260751001.
45. Colditz G.A., Bonita R., Stampfer M.J., et al. Cigarette smoking and risk of stroke in middle-aged women. NEJM 318 15 (1988) 937-941
46. Robbins A.S., Manson J.E., Lee I.-M., Satterfield Z., and Hennekens C.H. Cigarette smoking and stroke in a cohort of U.S. male physicians. Annals of Internal Medicine 120 (1994) 458-462
47. Tverdal A., Thelle D., Stensvold I., Leren P., and Bjartveit K. Mortality in relation to smoking history: 13 years' follow-up of 68 000 Norwegian men and women 35-49 years. Journal of Clinical Epidemiology 46 5 (1993) 475-487
48. Slattery ML. CYP1A1, cigarette smoking, and colon and rectal cancer 160. 2004:842-52.
49. Viswanathan A.N. Smoking and the risk of endometrial cancer: results from the Nurses' Health Study. International Journal of Cancer 114 (2005) 996-1001
50. Zhang B. Smoking cessation lung cancer mortality in a cohort of middle-aged Canadian women. Annual Review of Epidemiology 15 (2005) 302-309
51. Zeegers M.P. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89 (2000) 630-639
52. Malarcher A.M., Schulman J., Epstein L.A., et al. Methodological issues in estimating smoking-attributable mortality in the United States. AJE 152 6 (2000) 573-584
53. Melse J.M., Essink-Bot M.L., Kramers P.G., Hoeymans N., and Dutch Burden of Disease Group. A national burden of disease calculation: Dutch disability-adjusted life-years. American Journal of Public Health 90 8 (2000) 1241-1247
54. Stouthard M.E.A., Essink-Bot M.L., Bonsel G.J., et al. Disability weights for diseases in The Netherlands (1997), Department of Public Health. Erasmus University Rotterdam
55. van Baal P.H.M., Hoeymans N., Hoogenveen R.T., de Wit G.A., and Westert G.P. Disability weights for comorbidity and their influence on health-adjusted life expectancy. Popul Health Metr 4 1 (2006) 1
56. van Baal PHM, Feenstra TL, Hoogenveen RT, de Wit GA. Cost Effectiveness Analysis with the RIVM Chronic Disease Model. 2005; RIVM Report 260706002.
57. Nyman J.A. Should the consumption of survivors be included as a cost in cost-utility analysis?. Health Economics 13 5 (2004) 417-427
58. van Baal PHM, Feenstra TL, Hoogenveen RT, de Wit GA, Brouwer WBF. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost utility ratio. Health Economics, in press.